Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Capital Expenditures (2021 - 2025)

Lucid Diagnostics (LUCD) has disclosed Capital Expenditures for 5 consecutive years, with $28000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures changed N/A year-over-year to $28000.0, compared with a TTM value of $405000.0 through Sep 2025, up 91.04%, and an annual FY2024 reading of $296000.0, up 33.94% over the prior year.
  • Capital Expenditures was $28000.0 for Q3 2025 at Lucid Diagnostics, up from $25000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.1 million in Q2 2022 and bottomed at -$1.5 million in Q3 2022.
  • Average Capital Expenditures over 5 years is $143117.6, with a median of $28000.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 205100.0% in 2022, while the deepest fall reached 5439.29% in 2022.
  • Year by year, Capital Expenditures stood at $824000.0 in 2021, then plummeted by 75.36% to $203000.0 in 2022, then fell by 13.79% to $175000.0 in 2023, then skyrocketed by 48.0% to $259000.0 in 2024, then tumbled by 89.19% to $28000.0 in 2025.
  • Business Quant data shows Capital Expenditures for LUCD at $28000.0 in Q3 2025, $25000.0 in Q2 2025, and $93000.0 in Q1 2025.